Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

Authors

  • Graciela S. Alarcóan MD, MPH,

    Professor of Medicine, Corresponding author
    1. Multipurpose Arthritis Center, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, and the Birmingham Veterans Administration Medical Center
    • MD, MPH, The University of Alabama at Birmingham, 603 MEB, UAB Station, Birmingham, AL 35294
    Search for more papers by this author
  • Irene C. Tracy,

    Research Medicine
    1. Multipurpose Arthritis Center, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, and the Birmingham Veterans Administration Medical Center
    Search for more papers by this author
  • Warren D. Blackburn Jr. MD

    Assistant Professor of Medicine
    1. Multipurpose Arthritis Center, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, and the Birmingham Veterans Administration Medical Center
    Search for more papers by this author

Abstract

In an effort to understand the prognostic features that may influence the probability of a patient's continuing to take methotrexate (MTX) over time, we studied 152 rheumatoid arthritis patients treated with MTX between 1981 and 1986. The overall probability of continuing to take MTX was 71.2% at 1 year, 55.5% at 3 years, 50% at 5 years, and 49% at 6 years. By univariate analysis, patients who started MTX therapy later in the study, American blacks, younger patients, those with less severe disease, and those with less frequent or less severe toxic events appeared to have a better probability of continuing the drug therapy. When these parameters were evaluated by multivariate analysis, only the time when MTX was started and the occurrence of toxic effects independently influenced the probability of continuing MTX. Thus, by current practice standards, toxic effects emerge as the main reason for MTX discontinuation.

Ancillary